Document Type

Article

Publication Date

August 2018

Patent Number

10039785

CPC

A61K 35/16, A61K 2035/122, A61K 35/44, A61K 31/00, A61K 38/17, A61K 48/00, C07H 21/04, C07K 14/435, C07K 14/47, C07K 14/575, C12N 5/06, C12N 9/00, C12N 9/64, C12P 21/02, C12Q 1/68

Abstract

Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.

Application Number

15/195243

Assignees

University of South Florida

Filing Date

06/28/2016

Download

Share

COinS